EFFECT OF CATECHOL-O-METHYLTRANSFERASE INHIBITION ON BRAIN UPTAKE OF [F-18] FLUORODOPA - IMPLICATIONS FOR COMPARTMENTAL MODELING AND CLINICAL USEFULNESS
G. Leger et al., EFFECT OF CATECHOL-O-METHYLTRANSFERASE INHIBITION ON BRAIN UPTAKE OF [F-18] FLUORODOPA - IMPLICATIONS FOR COMPARTMENTAL MODELING AND CLINICAL USEFULNESS, Synapse, 30(4), 1998, pp. 351-361
The efficacy of levo-DOPA in the treatment of Parkinson's disease is p
otentiated by blockade of its peripheral metabolism with inhibitors of
catechol-O-methyltransferase (COMT). Some COMT inhibitors may act ent
irely in the periphery (nitecapone, OR-462), while others may also hav
e some activity in brain (entacapone, OR-611). We used positron emissi
on tomography (PET) to test the effects of these two COMT inhibitors o
n the plasma kinetics and brain metabolism of the levo-DOPA analog 6-[
F-18]fluoro-L-dopa (FDOPA) in cynomolgus monkeys, employing a compartm
ental model for the assay of DOPA decarboxylase activity in living bra
in. Four monkeys each underwent two PET scans in the baseline conditio
n, one PET scan after treatment with OR-462 (15 mg/kg, i.v.), and one
PET scan after treatment with OR-611 (15 mg/kg, i.v.). Pharmacokinetic
analysis of FDOPA metabolism in plasma indicated that these compounds
blocked peripheral COMT activity by 80% for at least 60 minutes. Both
COMT inhibitors increased the net availability of FDOPA in circulatio
n, and increased the ratio of the radioactivity concentrations in stri
atum and occipital cortex, suggesting that [F-18]fluorodopamine synthe
sis in striatum was potentiated. However, OR-611 treatment reduced the
unidirectional (K-1(D)) and net (K-i) blood-brain clearances of FDOPA
, and also inhibited the rate of decarboxylation (k(3)(D)) of FDOPA in
striatum. These observations suggest that high doses of OR-611 may pa
rtially antagonize the cerebral utilization of levo-DOPA. We used the
present data to test the sensitivity of the compartmental model to the
physiological constraint that the blood-brain permeabilities of the O
-methylated plasma metabolite and FDOPA have a fixed ratio. In the gro
ups with COMT inhibition, the estimates of k(3)(D) were insensitive to
the magnitude of the permeability ratio. In the control group, the es
timate of k(3)(D) increased by 40% as the magnitude of the constrained
permeability ratio increased in the range of published estimates. (C)
1998 Wiley-Liss, Inc.